DailyIQ
Last updated3 minutes ago

CORT·Corcept Therapeutics Incorporated

$117.79
-3.40 (-2.81%)
Overnight$117.55-0.24 (-0.20%)
High
$122.81
Open
$121.83
Market Cap
13.12B
52W High
$126.38
Low
$117.42
P. Close
$117.79
P/E
237.77
52W Low
$28.66
Fwd P/E
26.76
DailyIQ Est.
$148.76
Inst. Ownership
37.9%
Short Interest
7.65%
Days to Cover
3.6
Technical Score (1D)
64
BULLISH
News Sentiment
48
MIXED
CORT is setting up for a potential resolution: BUY at 64 with firm momentum on the 1D chart. Sentiment at 48 is diverging from the bullish bias, so confirmation still matters. $122.25 is the line bulls need to clear; $112.85 defines the risk if the attempt stalls. Momentum-driven buyers tend to show up only after $122.25 actually breaks, which means the setup can look identical for days before anything changes on the tape. That's the nature of breakout-watch conditions: the BUY read and firm momentum describe the pressure building, not the timing of when it releases.
LOW TARGET
$50 -57.6%
1 analysts
MEAN TARGET
$141 +19.7%
7 analysts
HIGH TARGET
$165 +40.1%
5 analysts
PRICE RANGE
$50.00 - $165.00
SB / B / H / S / SS
3/7/1/1/1
DAILYIQ EST.
$148.76 (+26.3%)
Bought (1Y)
0 shares
$0
Sold (1Y)
802,858 shares
$79.7M
Maduck SeanSee Remarks
Option Exercise24,587 shares2026-10-02
Maduck SeanSee Remarks
Sell8,744 shares2026-10-02
Maduck SeanSee Remarks
Sell15,843 shares2026-10-02
Maduck SeanSee Remarks
Option Exercise24,587 shares2026-10-02
Lyon Joseph DouglasSee Remarks
Option Exercise5,833 shares2026-10-02
83/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
98.3%
Net Margin
13.1%
Revenue CAGR
106.9%
Current Ratio
2.92x
Return on Equity
15.4%

EPS

EstBeatMiss
$0.03$0.26$0.50$0.74$0.97Q3'25Q3'26
QtrEstActual+/−
Q3'26$0.86 - -
Q3'25$0.14$0.16+18.5%

Revenue

EstBeatMiss
$187M$231M$275M$319M$363MQ3'25Q3'26
QtrEstActual+/−
Q3'26$343M - -
Q3'25 - $208M -

Market Data

CORT Stock Snapshot

NEUTRAL64/100
$117.55−$0.24 (0.2%)
Market cap
13.12B
P/E ratio
237.8
Day range
$117.42 – $122.81
News sentiment
48/100 · Neutral
Analyst target
$141.00 (+19.9%)
Consensus
Buy · 13 analysts
52-week range+310.2% off low · -7.0% from high
$28.66$126.38
Price $117.55 DailyIQ Est. $148.76

Neither side has the upper hand on CORT right now, and its momentum ranks near the middle of DailyIQ's universe. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Behaviour On Record

What CORT's own history says about today's numbers

Realized volatility (21d)
36.0% 21st pct
Below its peak
-2.3%
vs 200-day average
+71.1%
Up days (1y)
53%

Corcept Therapeutics Incorporated is currently running 36.0% annualised volatility over the last 21 sessions. Measured against CORT's own 13 years of daily returns rather than a market-wide average, that is the 21st percentile — unusually subdued by its own history, against a typical reading of 49.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

CORT is trading -2.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -39.3%, and the deepest was -62.5% in 2025. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +71.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 97th percentile — a wider gap than this stock usually carries. Over the past year CORT closed higher on 53% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, CORT finished the month higher 7 of 13 times, with a median return of +0.6% and an average of +1.1%. Its strongest month historically has been March at +10.1% on average, its weakest December at -6.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: CORT has opened more than 2% away from the prior close in 346 of 3,264 sessions (10.6% of the time), with the largest gaps running +17.2% and -32.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,266 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against CORT's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of CORT's sector?

Corcept Therapeutics Incorporated sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Biotechnology industry group, CORT ranks 13th of 15 tracked industries, lagging.

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73
Industry rank
#13 of 15

Options Market

What is the options market pricing for CORT?

CallsPuts

For Corcept Therapeutics Incorporated's nearest expiry (2027-01-15, 93 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.00), with at-the-money implied volatility around 0.8%. The options market is pricing roughly a ±0.4% move by that expiry — a range of about $120.07–$121.03.

Put/call ratio (2027-01-15)
0.00
ATM implied volatility
0.8%
Total open interest
20
Expected move by 2027-01-15
±0.4% ($120.07–$121.03)

Analyst Rating Changes

Are analysts turning bullish or bearish on CORT?

HC Wainwright & Co. most recently reiterated its rating on Corcept Therapeutics Incorporated to Buy on Sep 18, 2026 with a price target of $165. Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
HC Wainwright & Co. — Buy
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Sep 18, 2026HC Wainwright & Co.ReiteratedBuy$165
Jul 30, 2026Piper SandlerReiteratedOverweight$88 → $165
Jul 30, 2026Canaccord GenuityMaintainedBuy$150 → $161
Jul 30, 2026HC Wainwright & Co.MaintainedBuy$95 → $165
Jul 29, 2026Canaccord GenuityMaintainedBuy$135 → $150
Jul 27, 2026Wolfe ResearchDowngradePeer Perform → Underperform$50
May 28, 2026Canaccord GenuityMaintainedBuy$110 → $135
May 28, 2026HC Wainwright & Co.MaintainedBuy$75 → $95
May 13, 2026UBSUpgradeNeutral → Buy$44 → $72
May 4, 2026HC Wainwright & Co.MaintainedBuy$60 → $75
May 1, 2026Piper SandlerMaintainedOverweight$73 → $88
Mar 26, 2026Canaccord GenuityMaintainedBuy$100 → $110

ETF holders

ETFs holding CORT

News Sentiment Analysis

Sentiment gathered from recent headlines

48/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Investors in Corcept Therapeutics (CORT) should note that options activity has surged, with the November 20, 2026 $47.50 put exhibiting unusually high implied volatility. The spike indicates market participants expect a significant price swing, either upward or downward, before the option’s expiration. Analysts have raised earnings estimates for the current quarter, while none have lowered them, suggesting a cautiously optimistic view of the company’s fundamentals. The combination of heightened options volatility and positive earnings outlook points to a potential catalyst that could drive CORT’s share price sharply in either direction.
What did this article say?
Corcept Therapeutics’ stock fell on Oct. 6 during a broader medical sell‑off, but the decline was limited to near buy‑level support. The company’s earnings growth was highlighted as robust, suggesting underlying strength. The market reaction appeared to be a short‑term correction rather than a fundamental shift in the company’s prospects.
What did this article say?
On October 6, analysts highlighted concerns over Corcept’s declining earnings per share, noting a 16.1% annual drop over five years. The company’s stock had surged 201% in the past six months, yet the analysis suggested that the recent price rally may not reflect sustainable fundamentals. The report cautioned investors to exercise caution, presenting three reasons to consider selling CORT and recommending an alternative stock. The commentary emphasized that the EPS trend signals potential long‑term profitability issues, which could weigh on future valuation.
What did this article say?
On October 1, 2026, Corcept Therapeutics president Sean Maduck sold 25,000 shares of CORT for $2,906,601, reducing his direct holdings but leaving him with 119,655 shares under control. The transaction was filed as a Form 4 with the SEC and does not alter the company’s overall ownership structure. The sale reflects routine share liquidity for the insider and carries no immediate impact on CORT’s financial outlook.
What did this article say?
On October 1, 2026, Corcept Therapeutics chief accounting officer Joseph Douglas Lyon sold 10,000 shares of CORT for $1,160,731, as reported in a Form 4 filing. Lyon’s holdings remain at 5,683 shares, all held directly, and the sale does not change the company’s ownership dynamics. The transaction is a routine insider sale with no discernible effect on CORT’s operations or valuation.
What did this article say?
The article highlighted Corcept Therapeutics (CORT) as one of four low‑beta healthcare stocks suitable for investors wary of further Federal Reserve rate hikes. It noted that the September FOMC meeting raised rates to 3.75%‑4%, increasing market volatility and prompting a defensive tilt toward healthcare names. The piece emphasized that low‑beta stocks like CORT could provide stability in a high‑inflation environment. No specific guidance or earnings data for CORT were disclosed, and the recommendation was framed as a general sector strategy rather than a company‑specific forecast.
What did this article say?
The article compares the year‑to‑date performance of Corcept Therapeutics (CORT) with that of Aspen Pharmacare (APNHY). It notes that CORT is included in the same medical sector ranking as APNHY but does not report any new guidance, earnings, or material events for either company. The comparison focuses on sector rankings and analyst sentiment, with no indication of a significant change in outlook for CORT.
What did this article say?
Corcept Therapeutics released a second‑quarter investor letter highlighting robust commercial performance and expanding pipeline opportunities. The company reported solid sales growth driven by its flagship product portfolio and noted progress on several late‑stage development candidates targeting endocrine and metabolic disorders. Management emphasized strategic partnerships and a clear commercialization roadmap, reinforcing confidence in future revenue streams. The letter’s positive tone and concrete milestones suggest a material upside for the company’s valuation.
What did this article say?
Corcept Therapeutics (CORT) announced the retirement of Sean Maduck, President of its Endocrinology division, and the appointment of Justin Gunn to succeed him. The transition is scheduled to take effect in October, with Gunn assuming full responsibilities. The change is a routine leadership shuffle and does not signal any immediate operational or financial impact on the company.
What did this article say?
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has endorsed the combination of relacorilant and nab-paclitaxel for platinum‑resistant ovarian cancer, following encouraging Phase 2 and Phase 3 ROSELLA data. This regulatory backing confirms the clinical promise of CORT’s flagship therapy and is expected to lift investor confidence. The approval is likely to accelerate commercialization plans and could broaden the company’s oncology portfolio, reinforcing its undervalued status relative to peers.

Technical Analysis

Real-time indicators across multiple timeframes

64
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $3.17B combined position · 11 adding, 14 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy12,432,02311.14%$1.08B2026-08-07
Renaissance Technologies LLC▼ Sell5,261,6284.71%$457.50M2026-08-13
Vanguard Group Inc▼ Sell9,494,8228.51%$330.42M2026-01-29
FMR LLC (Fidelity)▲ Buy3,337,6182.99%$290.21M2026-08-13
AQR Capital Management LLC▲ Buy2,582,5612.31%$224.55M2026-08-14
Geode Capital Management, LLC▼ Sell2,532,1982.27%$220.21M2026-08-12
Morgan Stanley▲ Buy1,137,5591.02%$98.91M2026-08-13
D. E. Shaw & Co., Inc.▼ Sell883,0010.79%$76.78M2026-08-14
Northern Trust Corp▲ Buy753,7960.68%$65.54M2026-08-13
Two Sigma Investments, LP▼ Sell610,0780.55%$53.05M2026-08-14
Goldman Sachs Group Inc▼ Sell568,5190.51%$49.43M2026-08-14
Invesco Ltd.▼ Sell523,6690.47%$45.53M2026-08-14
Norges Bank▼ Sell487,0550.44%$42.35M2026-08-12
Bank of America Corp▲ Buy328,5650.29%$28.57M2026-08-14
JPMorgan Chase & Co▲ Buy253,1820.23%$22.65M2026-08-12
Millennium Management LLC▼ Sell152,5670.14%$13.27M2026-08-14
Citigroup Inc▼ Sell141,8090.13%$12.33M2026-08-03
Citadel Advisors LLC▼ Sell109,1050.10%$9.49M2026-09-02
Prudential Financial Inc▲ Buy99,7610.09%$8.67M2026-08-12
Voleon Capital Management LP▼ Sell91,9260.08%$7.99M2026-08-14
Janus Henderson Group plc▲ Buy164,0740.15%$6.61M2026-05-18
Man Group plc▼ Sell71,4910.06%$6.22M2026-08-14
Susquehanna International Group, LLP▼ Sell69,6840.06%$6.06M2026-08-14
Gotham Asset Management, LLC▲ Buy60,1810.05%$5.23M2026-08-14
Bridgewater Associates, LP▲ Buy57,6020.05%$5.01M2026-08-14
Q2 2026 flow:3.17M sh bought ($275.90M)2.88M sh sold ($250.02M)net +296.2K sh (+$25.89M)